Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chronic Myeloid Leukemia
37%
Malignant Neoplasm
35%
Hematologic Malignancy
30%
Leukemia
28%
Nilotinib
28%
Clinical Trial
26%
Azacitidine
25%
Myelodysplastic Syndrome
24%
Imatinib
23%
Protein Tyrosine Kinase
21%
Overall Survival
17%
Pevonedistat
17%
Disease
15%
Remission
14%
Chemotherapy
14%
Neoplasm
14%
Drug Development
13%
Dasatinib
12%
Myelofibrosis
11%
Enzyme Inhibitor
11%
Monoclonal Antibody
11%
Elacytarabine
11%
Vorinostat
11%
Troxacitabine
11%
Cytarabine
10%
Protein Tyrosine Kinase Inhibitor
9%
Pharmacokinetics
9%
Tolerability
8%
Acute Lymphoblastic Leukemia
8%
Phosphotransferase
7%
Protein P53
7%
Ephrin Receptor
7%
Isocitrate Dehydrogenase 2
7%
Maximum Tolerated Dose
6%
Biological Product
6%
Acute Leukemia
6%
Drug Resistance
6%
Adenosine Triphosphate
6%
Phosphotransferase Inhibitor
6%
Combination Therapy
5%
Enasidenib
5%
Retinoic Acid
5%
Renal Cell Carcinoma
5%
Venetoclax
5%
Ubiquitinated Protein
5%
Survivin
5%
Transcriptome
5%
Receptor
5%
Vosaroxin
5%
Medicine and Dentistry
Acute Myeloid Leukemia
96%
Disease
22%
Myelodysplastic Syndrome
21%
Hematologic Malignancy
20%
Clinical Trial
18%
Bone Marrow Biopsy
18%
Risk Stratification
17%
Protein P53
16%
Leukemia
16%
Neoplasm
15%
Overall Survival
14%
Nilotinib
14%
Malignant Neoplasm
13%
Targeted Therapy
13%
Acute Myelogenous Leukemia
13%
Biopsy
13%
Chronic Myelogenous Leukemia
12%
Myelofibrosis
12%
Ex Vivo
11%
Tumor Protein
11%
Venetoclax
11%
Hypomethylating Agent
11%
Drug Sensitivity
10%
Functional Genomics
9%
Diagnosis
9%
Imatinib
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Acute Lymphoblastic Leukemia
8%
Azacitidine
8%
Induction Chemotherapy
8%
Protein Tyrosine Kinase
7%
Monoclonal Antibody
7%
Myeloid Malignancy
7%
Megakaryocyte
7%
Gene Mutation
6%
Prognostication
6%
Cancer
6%
Drug Response
6%
Karyotype
6%
Combination Drug
6%
Tyrosine-Kinase Inhibitor
6%
Oncology
6%
Dasatinib
6%
Disease Assessment
5%
Bone Biopsy
5%
Entospletinib
5%
Elderly Patient
5%
Ontogeny
5%
Myeloid metaplasia
5%
Phase I Trials
5%
Keyphrases
Acute Myeloid Leukemia
68%
Chronic Myeloid Leukemia
36%
Leukemia
20%
Imatinib
20%
Myelodysplastic Syndrome
17%
First-in-class
17%
Nilotinib
15%
Hematological Malignancies
14%
Clinical Trials
13%
BCR-ABL
12%
Tyrosine Kinase Inhibitor
12%
Troxacitabine
11%
Dasatinib
11%
Inflammation
11%
EphA3
11%
NEDD8-activating Enzyme
11%
Pevonedistat
11%
Vorinostat
11%
Phase 1 Study
11%
Azacitidine
11%
Venetoclax
11%
Clonal Evolution
11%
Nup98
11%
Safety Profile
10%
Hypomethylating Agents
10%
Overall Survival
9%
Philadelphia Chromosome
9%
European LeukemiaNet
9%
Complete Remission
9%
Bone Marrow
9%
Chemotherapy
8%
Frontline Treatment
7%
Receptor Tyrosine Kinase
7%
Leukemia Therapy
7%
Risk Stratification
7%
Treatment Strategy
7%
Therapeutic Potential
7%
Pharmacokinetics
6%
High-risk Myelodysplastic Syndrome
6%
Older Adults
6%
MLN4924
6%
Biological Agents
6%
Tyrosine Kinase
6%
Tolerability
6%
Induction Chemotherapy
6%
PIM Kinase
6%
Dose Escalation
6%
Induced Apoptosis
6%
Cancer Therapy
6%
Survival Prognostication
6%
